Foghorn Therapeutics to Participate in Key Upcoming Healthcare Conferences in September 2025

Foghorn Therapeutics will participate in key healthcare conferences in September to discuss its innovative oncology-focused gene therapies.

Quiver AI Summary

Foghorn Therapeutics Inc., a biotechnology company focused on addressing serious diseases by correcting abnormal gene expression, announced its participation in several upcoming industry conferences, including Citi’s 2025 Biopharma Back to School Summit, the 2025 Wells Fargo Healthcare Conference, and the Morgan Stanley's 23rd Annual Global Healthcare Conference. The company's Gene Traffic Control® platform aims to transform treatment options, particularly in oncology, and is at the forefront of discovering new medicines targeting the chromatin regulatory system. Management will engage in one-on-one meetings at these events, highlighting Foghorn's commitment to developing innovative therapies. For more details, interested parties are encouraged to visit their website or follow the company on social media.

Potential Positives

Management is participating in multiple high-profile healthcare conferences, which can enhance visibility and investor interest in the company.
The focus on oncology and innovative Gene Traffic Control® platform positions Foghorn as a forward-thinking player in an important sector of biotechnology.
The ability to engage in one-on-one meetings at major conferences suggests a proactive approach to building relationships with potential investors and partners.

Potential Negatives

Management's participation in multiple conferences may suggest a need for visibility and confidence building in the company's pipeline and strategies, indicating potential underlying concerns about investor confidence or interest.

FAQ

What is Foghorn Therapeutics focusing on?

Foghorn Therapeutics is focusing on developing medicines that treat serious diseases by correcting abnormal gene expression, initially targeting oncology.

When will Foghorn participate in the Citi Biopharma Summit?

Foghorn will participate in the Citi’s 2025 Biopharma Back to School Summit on September 3, 2025.

What is the Gene Traffic Control® platform?

The Gene Traffic Control® platform is Foghorn’s proprietary system for discovering and developing medicines that target genetically determined dependencies.

Where can I find more information about Foghorn Therapeutics?

For more information, you can visit Foghorn Therapeutics' website at www.foghorntx.com.

Who can I contact for media inquiries about Foghorn?

You can contact Karin Hellsvik at Foghorn Therapeutics via email at [email protected] for media inquiries.

Disclaimer: This is an AI-generated summary of a press release distributed by GlobeNewswire. The model used to summarize this release may make mistakes. See the full release here.

$FHTX Hedge Fund Activity

We have seen 45 institutional investors add shares of $FHTX stock to their portfolio, and 38 decrease their positions in their most recent quarter.

Here are some of the largest recent moves:

DEERFIELD MANAGEMENT COMPANY, L.P. added 2,477,989 shares (+318.7%) to their portfolio in Q2 2025, for an estimated $11,646,548
BLACKROCK, INC. added 233,232 shares (+11.7%) to their portfolio in Q2 2025, for an estimated $1,096,190
CANTOR FITZGERALD, L. P. added 150,000 shares (+inf%) to their portfolio in Q2 2025, for an estimated $705,000
RAYMOND JAMES FINANCIAL INC added 148,940 shares (+6.7%) to their portfolio in Q2 2025, for an estimated $700,018
GEODE CAPITAL MANAGEMENT, LLC added 116,979 shares (+16.9%) to their portfolio in Q2 2025, for an estimated $549,801
AMERIPRISE FINANCIAL INC added 112,237 shares (+inf%) to their portfolio in Q2 2025, for an estimated $527,513
ROCKWOOD WEALTH MANAGEMENT, LLC removed 107,329 shares (-100.0%) from their portfolio in Q2 2025, for an estimated $504,446

To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.

$FHTX Analyst Ratings

Wall Street analysts have issued reports on $FHTX in the last several months. We have seen 2 firms issue buy ratings on the stock, and 0 firms issue sell ratings.

Here are some recent analyst ratings:

JMP Securities issued a "Market Outperform" rating on 05/15/2025
HC Wainwright & Co. issued a "Buy" rating on 04/30/2025

To track analyst ratings and price targets for $FHTX, check out Quiver Quantitative's $FHTX forecast page.

$FHTX Price Targets

Multiple analysts have issued price targets for $FHTX recently. We have seen 3 analysts offer price targets for $FHTX in the last 6 months, with a median target of $13.0.

Here are some recent targets:

Silvan Tuerkcan from JMP Securities set a target price of $9.0 on 05/15/2025
Andres Maldonado from HC Wainwright & Co. set a target price of $13.0 on 04/30/2025

Full Release

CAMBRIDGE, Mass., Aug. 27, 2025 (GLOBE NEWSWIRE) -- August 27, 2025 -- Foghorn ^® Therapeutics Inc. (Nasdaq: FHTX), a clinical-stage biotechnology company pioneering a new class of medicines that treat serious diseases by correcting abnormal gene expression, today announced that management will participate in Citi’s 2025 Biopharma Back to School Summit, 2025 Wells Fargo Healthcare Conference, and Morgan Stanley 23rd Annual Global Healthcare Conference. With an initial focus in oncology, Foghorn’s Gene Traffic Control ^® platform and resulting broad pipeline have the potential to transform the lives of people suffering from a wide spectrum of diseases.

Citi’s 2025 Biopharma Back to School Summit

Date: Wednesday, September 3, 2025
Management will participate in one-on-one meetings

2025 Wells Fargo Healthcare Conference

Date: Thursday, September 4, 2025
Management will participate in one-on-one meetings

Morgan Stanley 23 ^rd Annual Global Healthcare Conference

Date: Monday, September 8, 2025
Management will participate in one-on-one meetings

About Foghorn Therapeutics
Foghorn ^® Therapeutics is discovering and developing a novel class of medicines targeting genetically determined dependencies within the chromatin regulatory system. Through its proprietary scalable Gene Traffic Control ^® platform, Foghorn is systematically studying, identifying, and validating potential drug targets within the chromatin regulatory system. The Company is developing multiple product candidates in oncology. Visit our website at www.foghorntx.com for more information on the Company, and follow us on X and LinkedIn .

Contact:
Karin Hellsvik, Foghorn Therapeutics Inc.
[email protected]